Scitop Bio Signed a Joint Development Contract with Jiangzhong Pharmaceutical

Scitop Bio disclosed its third quarterly report and investor activity sheet. Revenue profit continued to maintain double-digit growth in both directions, and the edible probiotics segment continued to lead the way, with sales revenue up 166.86% year-on-year. At the same time, Scitop Bio also disclosed the joint technology development contract of probiotic live bacteria new drug with Jiangzhong Pharmaceutical. As disclosed in the announcement, the goal of the project is to obtain FDA clinical phase I clearance for new probiotic drugs for IBS and IBD use by the end of 2023. The final research and development results and the related intellectual property rights will be jointly held by both parties. (Source: baijiahao)